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Abstract
Tamoxifen is the most prescribed selective estrogen receptor (ER) modulator in patients with ER-positive breast cancers.
Tamoxifen requires the transcription factor paired box 2 protein (PAX2) to repress the transcription of ERBB2/HER2. Now,
we identified that PAX2 inhibits cell growth of ER+/HER2− tumor cells in a dose-dependent manner. Moreover, we have
identified that cell growth inhibition can be achieved by expressing moderate levels of PAX2 in combination with tamoxifen
treatment. Global run-on sequencing of cells overexpressing PAX2, when coupled with PAX2 ChIP-seq, identified common
targets regulated by both PAX2 and tamoxifen. The data revealed that PAX2 can inhibit estrogen-induced gene transcription
and this effect is enhanced by tamoxifen, suggesting that they converge on repression of the same targets. Moreover, PAX2
and tamoxifen have an additive effect and both induce coding genes and enhancer RNAs (eRNAs). PAX2–tamoxifen
upregulated genes are also enriched with PAX2 eRNAs. The enrichment of eRNAs is associated with the highest expression
of genes that positivity regulate apoptotic processes. In luminal tumors, the expression of a subset of these proapoptotic
genes predicts good outcome and their expression are significantly reduced in tumors of patients with relapse to tamoxifen
treatment. Mechanistically, PAX2 and tamoxifen coexert an antitumoral effect by maintaining high levels of transcription of
tumor suppressors that promote cell death. The apoptotic effect is mediated in large part by the gene interferon regulatory
factor 1. Altogether, we conclude that PAX2 contributes to better clinical outcome in tamoxifen treated ER-positive breast
cancer patients by repressing estrogen signaling and inducing cell death related pathways.
Introduction
Breast cancer is the most common malignancy in women
and overall is the second most common cancer worldwide,
with more than 2 million new cases diagnosed globally
each year. Breast cancer is also a heterogenous disease at
both histological and molecular levels. According to gene
expression patterns in tumors, breast cancer is classified
into several intrinsic molecular subtypes, and each sub-
type differs in the expression of key molecular markers
and prognosis [1]. Despite the complexity, around 70% of
tumors are composed of the estrogen receptor (ER) α-
positive luminal subtype. Endocrine treatments that target
estrogen signaling are the main strategies in the adjuvant
setting and their use in the neoadjuvant scenario is gaining
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progressive interest, particularly in the postmenopausal
population. For decades, the selective ER modulator
tamoxifen (Tam) has been the mainstay of the adjuvant
treatment for premenopausal women with breast cancer
and it is still widely used in this context. Tam is a che-
mical compound that antagonizes estrogen action by
competing with estrogen for binding to ER. By contrast,
the use of aromatase inhibitors (AIs) is the preferred
adjuvant treatment in postmenopausal women. AIs inhibit
the synthesis of estradiol and then prevent the activation
of ER. Moreover, Tam is the treatment of choice in
postmenopausal women who do not tolerate an AI [2].
Previously, we and others reported that paired box 2
protein (PAX2) is a key factor in breast cancer by
repressing the transcription of ERBB2/HER2 in ER-
positive (ER+) breast cancer [3, 4]. Moreover, it has been
described that high level of PAX2 is associated with better
survival in Tam treated ER+ breast cancer patients [3, 5].
However, it is not clear how PAX2 can modulate ER
activity in ER+ and HER2-negative (HER2−) tumors.
PAX2 is a protein that belongs to the paired box tran-
scription factor family with DNA binding domains
represented by paired domain. PAX2 plays an important
role in tissue development, such as the renal tissue mor-
phogenesis [6], and progesterone-dependent mammary
growth. PAX2 can either activate or repress gene tran-
scription by recruiting regulatory proteins such as PTIP
[7] or GRG4 [8, 9] through protein interaction with the C-
terminal transactivation domain. PTIP or GRG4 further
recruit enzymes that catalyze histone modifications to
activate or repress transcription, respectively [7, 10].
In this study, we have characterized the role of PAX2 in
ER+/HER2− breast cancer cells, specifically under condi-
tions where ER has been inhibited with an antagonist. We
have used Global Run-On sequencing (GRO-seq) analysis
to reveal substantial transcriptional alterations in cells
expressing different levels of PAX2. Moreover, we show
that increased PAX2 expression improves Tam response by
two means. Firstly, PAX2 represses the transcription of
estrogen-induced genes in an additive manner with Tam
treatment leading to a cell growth inhibition. Secondly,
PAX2 induces both coding gene transcripts and enhancer
RNAs (eRNAs) nearby genes enriched at cell death pro-
cesses. PAX2 ChIP-seq revealed that Tam enhances the
binding of PAX2 toward the promoter regions of proa-
poptotic genes with PAX2-induced eRNAs, contributing to
increased gene expression. The high expression of three of
these genes predicts survival in luminal tumors and the
expression of them is significantly reduced in tumors with
relapse to Tam. One key target gene is interferon regulatory
factor-1 (IRF1), which is a proapoptotic factor. The
expression of PAX2 and its target gene IRF1 is essential for
Tam-induced apoptosis.
Results
The levels of PAX2 expression determine the benefit
of Tam to inhibit cell growth
The role of PAX2 regulating the transcription of ERBB2/
HER2 in breast cancer was previously reported in ER+
cells treated with Tam [4, 5]. The repression of ERBB2
expression by ER-Tam was shown to require PAX2.
Moreover, clinical studies have observed a significant
association between high expression of PAX2 and better
disease-free survival in patients treated with Tam [5]. Now,
we aimed to investigate how increased levels of PAX2
expression improved Tam action in ER+/HER2− cell line.
We used MCF-7 cells, which express moderate levels of
PAX2 as reported previously [4]. We created an inducible
PAX2 overexpressing MCF-7 cell line and tested the
expression of the ectopic PAX2 on cell viability. MCF-7
PAX2 overexpressing cells were plated in estrogen-rich, full
culture media and treated with Dox to induce the ectopic
overexpression of PAX2. After 16 h of Dox treatment at
different concentrations, PAX2 levels were increased in a
Dox dependent manner (Fig. 1a). Next, we investigated
how PAX2 overexpression influenced the basal growth of
cells and whether Tam treatment affected this. Cells were
treated with three concentrations of Dox (0, 25, and 50 ng/
ml) to induce different amounts of PAX2 expression and
subsequently treated with vehicle (Veh) or Tam. The degree
of cell growth inhibition correlated with PAX2 expression
levels (Fig. 1b), confirming the previous data implicating
PAX2 as a repressor in breast cancer [5]. Moreover, the
treatment with Tam resulted in greater cell growth inhibi-
tion with intermediate levels of PAX2 expression, sug-
gesting that Tam can potentiate the antiproliferative effects
of patients with moderate expression of PAX2. Altogether,
these findings support the hypothesis that high PAX2
expression inhibits cell growth and PAX2 expression
improves the efficacy of Tam in ER+/HER2− cancer cells.
PAX2–Tam regulates the transcription of gene
transcripts related to cell growth and death
In order to investigate the precise role of PAX2 and Tam in
ER+/HER2− tumors, we first determined the expression of
coding genes and eRNAs regulated by PAX2, Tam, or the
combination of both. MCF-7 PAX2 overexpressing cells
were plated in full culture media and treated with Dox
(50 ng/ml Dox) to induce high expression of PAX2. After
16 h of Dox treatment, 1 µM Tam was added to control or
Dox treated cells for 6 h. In order to determine both coding
genes and eRNAs, we performed GRO-seq for each treat-
ment (Veh, Tam, Dox (PAX2), and Tam+Dox (PAX2))
with two biological replicates. Libraries were prepared and
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sent for high throughput sequencing, with a minimum of 14
million aligned reads. First, differentially expressed coding
genes were called as described in the methods and only
genes above 1.5-fold change (treatments vs control cells)
and FDR < 0.05 were considered significantly regulated. In
total, 1054 differentially expressed genes were identified in
at least one of the three treatments (Fig. 2a): 156 genes in
Tam treatment (36 up and 120 down), 868 genes in PAX2
overexpression (489 up and 379 down), and 985 in Tam
treated cells overexpressing PAX2 (508 up and 477 down).
The overlap of up- and downregulated genes between dif-
ferent treatments is shown in Fig. 2b, c. Cells over-
expressing PAX2 were largely unaffected by cotreatment
with Tam (Fig. 2b). However, a subset of genes (90 genes)
was significantly upregulated in conditions of high PAX2
expression and Tam treatment (Fig. 2c). In cells without
PAX2 overexpression, we identified a very limited overlap
with Tam-induced genes but the majority of Tam-repressed
genes (62.6%) were also downregulated in PAX2 over-
expressing cells. Examples of genes regulated only by
PAX2 or regulated by both PAX2 and Tam are shown at the
bottom of Fig. 2b, c.
In order to characterize the biological effect of PAX2 and
Tam regulated transcriptome, pathway enrichment analysis
of differentially regulated genes detected by GRO-seq was
performed. As predicted, significant enrichment in estrogen
response signaling was observed in genes downregulated by
Tam or PAX2 (Supplementary Fig. 1A, B), providing
support that PAX2 elicits its antiproliferative effects in ER+
cancer cells, via modulation of ER target genes. Moreover,
when analyzing genes downregulated by both Tam and
PAX2, estrogen signaling was the most enriched pathway,
with transmembrane receptor protein tyrosine kinase sig-
naling pathway also enriched (Supplementary Figs. 1C and
2). When focusing specifically on genes induced by PAX2
expression or Tam as single treatments, we observed
enrichment for two cytokine-related pathways (TNFα sig-
naling via NFκB and interferon alpha response) in PAX2
but not in Tam group of genes (Supplementary Fig. 3A, B).
The most enriched pathways observed in PAX2 over-
expressing cells with Tam were hallmark of TNFα signaling
and p53 (Supplementary Fig. 3C), suggesting that PAX2
and Tam might induce transcription of tumor suppressors.
Next, we aimed to investigate whether the changes in
transcription due to Tam treatment might be directly regu-
lated by PAX2. For that, we performed chromatin immu-
noprecipitation (ChIP)-sequencing of PAX2 in MCF-7 cells
overexpressing PAX2 and treated with Tam. We had
assessed numerous endogenous PAX2 antibodies for ChIP-
seq but none could be validated. As such, we exploited the
PAX2 overexpressing system, since PAX2 was tagged with
hemagglutinin (HA). As control, we used cells without
PAX2 overexpression. For that, MCF-7 PAX2 over-
expressing cells were plated in full culture media and
treated with 50 ng/ml of Dox to induce the ectopic over-
expression of PAX2. After PAX2 overexpression, 1 µM
Tam was added to the cells for 6 h and two biological
replicates (Supplementary Fig. 4) of ChIP-seq were con-
ducted as described in “Methods.” We identified a total of
84,730 PAX2 peaks in PAX2 overexpressing cells and
90,577 peaks in PAX2 overexpressing cells treated with
Tam (Supplementary Fig. 5A, B). Almost all the PAX2
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Fig. 1 PAX2 expression in
ER+/HER2− tumors is
associated with response to
tamoxifen. a Protein blot of
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binding events for non-Tam treated cells where shared with
the peaks found in cells treated with Tam (92%). Moreover,
we observed a modest increase of PAX2 binding in Tam
treated cells (14% of peaks were only observed in PAX2
expressing cells treated with Tam). We investigated what
fraction of PAX2-regulated genes had PAX2 binding events
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nearby (±1.5 kb) their transcription start sites (TSS). Inter-
estingly, we found that more than 60% of the PAX2 and
Tam upregulated genes had at least one PAX2 binding site
adjacent to their TSS (Supplementary Fig. 5C). Conversely,
we found a moderate fraction (36%) of PAX2 down-
regulated genes with PAX2 sites (Supplementary Fig. 5C).
In support of the enrichment of p53 and TNFα signaling
pathways, we observed that PAX2 binding in cells treated
with Tam was significantly increased around TSS of genes
enriched within those pathways (Fig. 2d). Importantly, the
impact of Tam on PAX2 binding correlated positively with
the expression of genes enriched in TNFα and p53 path-
ways (Fig. 2d and Supplementary Fig. 5D) but not to non-
PAX2-regulated genes (Supplementary Fig. 6). Altogether,
our findings supported the hypothesis that PAX2 has a dual
effect: it is able to repress the transcription of genes in
estrogen response and to activate transcription of genes
related to cell death and growth arrest. Furthermore, the
PAX2 effect was enhanced by simultaneous Tam adminis-
tration (Supplementary Figs. 7 and 8).
PAX2–Tam induce transcripts with clinical outcome
Our findings have suggested that PAX2 induces the
expression of proapoptotic genes by interacting to the pro-
moters of their target genes. Moreover, it is well known that
gene transcription is regulated by the expression of eRNAs,
which are located mainly at intergenic regions. Hence, we
hypothesized that PAX2 might be binding to nearby
enhancer regions to control the transcription of eRNAs. For
that we determined whether PAX2, Tam, or the combina-
tion of both might impact the expression of eRNAs at
intergenic regions. The differentially expressed eRNAs at
intergenic regions were called as described in “Methods”
and only eRNAs with 1.5-fold change (treatments vs control
cells) and FDR < 0.05 were considered significantly regu-
lated. In total, 620 differentially expressed eRNAs were
identified in at least one of the three treatments (Supple-
mentary Fig. 9): 77 in Tam treatment (9 up and 68 down),
518 in PAX2 overexpression (173 up and 245 down), and
507 in Tam treated cells overexpressing PAX2 (209 up and
298 down). Next, we determined how many of the PAX2-
regulated genes were associated with PAX2 eRNAs. Our
findings revealed that 16 PAX2 upregulated genes were
associated with PAX2-induced eRNAs. Then, we compared
the expression of the upregulated genes with or without
PAX2-induced eRNAs. The results revealed that PAX2
upregulated genes with eRNAs were significantly upregu-
lated compared to the upregulated genes without eRNAs
(Fig. 3a). Importantly, those genes were also enriched in
positive regulation of apoptosis (Fig. 3b). Based on our
findings, we hypothesized that the expression of that subset
of PAX2 highly expressed genes might prevent breast
cancer tumors to relapse on Tam treatment. To validate our
hypothesis, we determined whether the expression of these
genes (Fig. 3c) might have an impact in patient survival and
metastases in luminal breast cancer patients. Our analysis
revealed that overexpression of 2 out of these 16 genes
(IRF1 and MAL) was associated with longer survival. In
addition, we identified that the overexpression of one of
those genes (BDH1) was associated with a significant
relapse-free survival (RFS). Next, we determined the
expression of BDH1 in paired tumor samples (primary and
metastatic) from patients who initially responded but
develop resistance to Tam. Our analysis indicated that the
expression of BDH1 gene was significantly downregulated
in metastatic tumors when compared to the primary tumors
in four out of five patients investigated (Fig. 3d). The high
expression of BDH1 induces autophagy [11], which is
considered a preliminary step to apoptosis. Overall, our
findings were supporting the idea that PAX2–Tam induces
massive transcription of genes that promotes cell death in
breast cancer patients and that the loss of their expression is
associated with resistance to Tam.
PAX2 and Tam-induced apoptosis is mediated by
IRF1
Next, we aimed to investigate the putative role of PAX2 and
Tam in regulating apoptosis. Therefore, we explored the
PAX2 upregulated genes with eRNAs, and among them we
identified that IRF1, a tumor suppressor gene, was one of
the top PAX2-induced genes. We validated that IRF1 pro-
tein level was significantly upregulated by PAX2 over-
expression (Fig. 4a). PAX2 ChIP followed by real-time
PCR confirmed PAX2 binding at both the promoter and
enhancer of the IRF1 gene (Fig. 4b), indicating direct
transcriptional regulation. Considering that IRF1 is an
important transcription factor mediating apoptosis in breast
cancer, we hypothesized that the induction of genes related
to growth arrest and cell death by PAX2 could be partially
attributed to IRF1 upregulation. In order to assess this
Fig. 2 PAX2 regulates a gene signature in MCF-7 cells. a Volcano
plots of genes regulated in different treatments (tamoxifen, PAX2, and
PAX2–tamoxifen) detected in GRO-seq experiment. b, c upper panel:
Venn diagrams showing the overlap of up or downregulated genes
detected in GRO-seq between different treatments respectively. b, c
lower panel: genome browser examples illustrating different patterns
of regulation of PAX2 up or downregulated genes. d Box plots of
sequencing data for PAX2-HA ChIP-sequencing (left) and gene
expression (right) of PAX2-regulated genes with PAX2-HA binding
sites at their TSS. Genes enriched at TNF (top) and p53 (bottom)
signaling are indicated. The ChIP-sequencing data are indicated as fold
change of PAX2 binding of tamoxifen (DoxTam) vs non-tamoxifen
(Dox). The expression data are indicated as log2 fold change of cells
overexpressing PAX2 (dox) or overexpressing PAX2 and tamoxifen
treatment (DoxTam) relative to non-PAX2 overexpressing cells (Veh).
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Fig. 3 PAX2 upregulated genes with eRNAs predict tamoxifen
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String of BDH1 was investigated in both samples and in each of the
five patients.
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hypothesis, two different siRNAs against IRF1 were vali-
dated, with differing degrees of silencing (Fig. 4c). The
dependence of IRF1 on PAX2-induced transcription was
assessed by real-time PCR in MCF-7-PAX2 cells trans-
fected with nontargeting siRNA or siRNAs targeting IRF1
(Fig. 4d and Supplementary Fig. 10). To complement the
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IRF1 knockdown work, IRF1 was ectopically over-
expressed in wild-type MCF-7 cell line (Fig. 4e, f). Tran-
scription of IRF1 dependent genes was activated by IRF1
overexpression in MCF-7 cells (Fig. 4f). Altogether, our
findings show that the transcription of a subset of
PAX2–Tam upregulated genes is dependent of IRF1.
Given the results that some of the PAX2 genes are
regulated by IRF1 and the expression of IRF1 predicts
survival in breast cancer patients, we examined whether
PAX2 was able to induce apoptosis through IRF1 in MCF-7
cells. IRF1 can induce caspase and we therefore assessed
the status of caspase 8 and 7 with PAX2 overexpression.
The level of pro-caspase 8, 7, and activated cleaved caspase
7 increased when PAX2 was overexpressed, compared with
the nontreated control (Fig. 5a). Moreover, Tam enhanced
PAX2-induced apoptosis shown as increased cleaved cas-
pase 7 (Fig. 5a), suggesting that the combination of PAX2
overexpression and Tam could induce higher level of
apoptosis in MCF-7 cells. The finding was further validated
by real-time Annexin V staining assay, which showed
increased Annexin V signal in the combination of PAX2
overexpression and Tam compared with either individual
treatment (Fig. 5b and Supplementary Fig. 11). Then, by
using IRF1 siRNAs we aimed to validate the role of IRF1 in
PAX2 mediated apoptosis. The knock down of IRF1 could
revert the induction of caspases 7 and 8 and cleaved caspase
7 (Fig. 5c), and furthermore the Annexin V signal induced
by the combination of PAX2 overexpression and Tam (Fig.
5d and Supplementary Fig. 11). Based on the results above,
we conclude that PAX2 is able to induce apoptosis in MCF-
7 cells and that is enhanced by Tam treatment by upregu-
lating proapoptotic genes such as IRF1 (Fig. 5e). Con-
sidering the heterogeneous nature of breast tumor, a few key
experiments were repeated in another ER+/HER2 low cell
line ZR-75-1. Results showed that PAX2 could inhibit cell
proliferation and induce higher level of apoptosis (Annexin
V assay) together with Tam (Supplementary Fig. 12),
confirming the findings that discovered in MCF-7 as
described above.
Discussion
The results of this work have demonstrated that PAX2
induces the transcription of genes key for the initiation of
apoptosis in ER+/HER2− breast cancer cells. This effect
is mediated, in part, by the transcription factor IRF1,
which is directly upregulated by PAX2. IRF1 is an
important factor mediating the response to anti-estrogens
in ER+ breast cancer cells [12]. In fact, the down-
regulation of IRF1 protects cells from PAX2-induced
growth inhibition and apoptosis. At molecular level, IRF1
leads to the initiation of apoptosis by activating cell cycle
inhibitors such as p21cip1 or p27kip1, caspases (CASP1,
CASP3, CASP7, CASP8), and/or Fas ligand [13]. In
addition, IRF1 could also exert its function by facilitating
p53 acetylation, which can stabilize the protein [14, 15].
In agreement with this idea, we demonstrated that p53
protein level was increased by PAX2, whereas the mRNA
level remained unaffected (Supplementary Fig. 8G, H).
This concept is consistent with the fact that PAX2 and its
gene target IRF1 have an antitumor effect by promoting
apoptosis [12]. In addition, we have discovered that the
PAX2 apoptotic effect is enhanced by the anti-estrogen
drug Tam. Tam enhances the expression of some PAX2-
induced genes key in the control of p53 function. For
instance, Tam enhances the upregulation of RNF114B,
which functions as an E3 ubiquitin ligase for Pirh228
[16]. RNF144B binds and ubiquitinates Pirh2 for protea-
somal degradation, which is negative regulator of p53.
These findings support the idea that the expression of
PAX2-induced genes in luminal tumors might function as
a marker of good prognosis and also as a predictive factor
of benefit from Tam. Breast cancer patients with luminal
tumors expressing PAX2 might be responding better to
Tam in comparison to patients with undetectable PAX2
expression. The expression of PAX2 has a double effect in
luminal tumors: it induces transcription of proapoptotic
genes and represses the transcription of estrogen-induced
genes key to cell division. Therefore, by inhibiting the cell
Fig. 4 PAX2-induced transcription is partially dependent on IRF1.
a Western blotting showing IRF1 induction by PAX2 overexpression.
MCF-7-PAX2 cells were treated with Dox for 16 h, IRF1, PAX2, and
β-actin levels were determined with western blotting. b PAX2 (HA
antibody) ChIP experiment with MCF-7-PAX2 cells treated with
vehicle (Veh) and 50 ng/ml doxycycline (Dox). Two sites located at
IRF1 promoter (IRF1-P) or IRF1 enhancer (IRF1-E) were tested with
real-time PCR (n= 3, *p < 0.05, **p < 0.01). Pull-down DNA amount
was normalized to the input DNA of each sample, and data are pre-
sented as the percentage of input with ±s.d. as the error bar. c Western
blotting of MCF-7-PAX2 cells transfected with nontargeting siRNA
(siNT), and two siRNAs targeting IRF1 (siIRF1-1 and siIRF1-2).
MCF-7-PAX2 cells were transfected with siNT, or siIRF1. IRF1,
PAX2, and β-actin level were detected by Western blotting. IRF1
protein level was quantified by normalization against beta actin level.
d Real-time PCR analysis of genes upregulated by PAX2. MCF-7-
PAX2 cells were transfected with nontargeting siRNA (siNT) or
IRF1 siRNA followed by doxycycline treatment. mRNA levels of
genes were measured with real-time PCR, and result was normalized
first to UBC and then to the average of Veh sample. The data are
represented as the mean of independent replicates ± s.d. (n= 3, *p <
0.05, **p < 0.01). e MCF-7 cells were transfected with pCI-neo empty
vector or with increasing amount of pCI-neo-IRF1 vector. Forty-eight
hours after transfection, IRF1 and β-actin level was determined with
western blotting. f MCF-7 cells were transfected with pCI-neo empty
vector or with increasing amount of pCI-neo-IRF1 vector, then mRNA
levels of different genes were detected with real-time PCR, result was
normalized first to UBC and then to the average of Veh, and data are
presented as the percentage of input with ±s.d. as the error bar (n= 3,
*p < 0.05, **p < 0.01).
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Fig. 5 PAX2 induces apoptosis via IRF1. a Western blotting
showing induction of caspase 7 and 8 level by PAX2. MCF-7-PAX2
cells were treated with vehicle (Veh), 50 ng/ml doxycycline (Dox),
1 μM tamoxifen (Tam) or the combination of both for 48 h, then whole
cell lysate was prepared and analyzed by using western blotting with
caspase 7, caspase 8, and RPL13a antibodies, RPL13a is used as
loading control. Cleaved caspase 7 was quantified normalization
against RPL13a. b MCF-7-PAX2 cells were transfected with siNT or
siIRF1 for 24 h, then treated with or without 50 ng/ml doxycycline
(Dox) for 48 h. Whole cell lysate was prepared and analyzed with
western blotting with caspase 7, caspase 8, and RPL13a antibodies. c,
d Real-time Annexin V assay showing PS externalization. MCF-7-
PAX2 cells were transfected with siNT, or siIRF1 followed by treat-
ments with vehicle (Veh), 50 ng/ml doxycycline (Dox), 1 μM tamox-
ifen (Tam), or the combination of both. PS externalization was
measured according to the methods session. The data are represented
as the mean of independent replicates ± s.d. (n= 5). e The model of
actions of PAX2 in ER-positive breast cancer cells.
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division and also by inducing apoptosis PAX2 and Tam
might prevent the tumor growth and ultimately lead to
more efficient Tam response.
The results of this study suggest that the expression of
PAX2 is associated to a better prognosis in patients with
luminal tumors. Moreover, our findings suggest that
patients with increased PAX2 protein levels might show
better outcomes for Tam treatment. In agreement with our
findings, our clinical data support that ER+/PAX2
+/HER2− patients without Tam treatment (or any endo-
crine treatment) have shorter RFS compared to patients
treated with Tam (median RFS 5.3 years in Tam vs 4 years
in nontreated patients; data not shown). In both the
neoadjuvant and adjuvant scenarios, Tam has shown to be
slightly inferior to AI both in the postmenopausal popula-
tion with early breast cancer in the premenopausal patients
on GnRH analogs [2]. One possible explanation of the
poorer results of Tam could be due to the fact that only
40–60% of these luminal patients are positive for the
expression of PAX2 [3, 17], which might be specifically
predictive of Tam response. If that was the case, it is rea-
sonable to think that Tam might provide similar benefit than
AI in a well selected population for PAX2 positivity, and
the neoadjuvant scenario would be the most appropriate
platform to test this hypothesis. Regardless of that, AI are
associated to a non-meaningless toxicity (arthromyalgies,
asthenia, sexual dysfunction among others) leading to
endocrine therapy discontinuation in a substantial percen-
tage of women, for whom Tam is still a suitable alternative.
Whether the expression of PAX2 upregulated transcripts is
a better indicative marker for Tam outcome than PAX2
itself in the neoadjuvant setting should be evaluated in the
future.
Sequencing data
The GEO accession numbers of the data are GSE139928
and GSE140060 for GRO-seq and ChIP-seq, respectively.
Methods
Cell culture
ER+ breast cancer and HER2− cell lines MCF-7 and ZR-
75-1 were purchased from American Type Culture Collec-
tion (Manassas, VA). MCF-7 is cultured in Dulbecco’s
Modified Eagle Medium (41966-052, Gibco) supplemented
with 10% of fetal bovine serum (10500-064, Gibco), and
ZR-75-1 is cultured in RPMI-1640 medium (61870010,
Gibco) supplemented with 10% FBS. MCF-7-PAX2 stable
cell line is kept in additional 200 μg/ml of hygromycin B
and 5 μg/ml puromycin.
Plasmids and cloning construction
pLV.ExSi.P/Hygro-CMV-TET3G and pLV.ExSi.P/Puro-
TRE3G-PAX2/HA vectors were purchased from Cyagen
(Santa Clara, CA, USA). pCI-Neo mammalian over-
expression vector was purchased from Promega (E1841).
IRF1 full length sequence was amplified from MCF-7
cDNA with corresponding primers. IRF1 cDNA and PAX2-
HA sequence were cloned into pCI-neo with NheI and MluI
restriction sites.
Transfection
MCF-7-PAX2-HA cells were transfected with siRNAs tar-
geting IRF1 (Thermo Fisher, AM16708, siRNA ID: 115266
(siIRF1-1) and 115267 (siIRF1-2)), siControl Non-targeting
(siNT) (SI03650318 from Promega) using Lipofectamine
RNAiMax (Life technologies) to a final concentration of
20 nM following the reverse transfection protocol from the
manufacturer in full culture media.
For transient transfection with pCI-neo-IRF1 or PAX2
vector, MCF-7 and ZR-75-1 cells were plated into a six-
well plate around 70% confluences. Transfection was car-
ried out with Lipofectamine 3000 (Invitrogen) following the
manufacturer’s protocol.
Lentivirus production and stable cell line generation
Lentiviral delivery plasmid pLV.ExSi.P/Hygro-CMV-
TET3G and pLV.ExSi.P/Puro-TRE3G-PAX2/HA were
cotransfected respectively with packaging plasmids into
293T cells plated in 10 cm dishes. Collection of super-
natants was done twice at 48 and 72 h post transfection
followed by concentration with Lenti-X concentrator
(#631232, Clontech). In order to generate MCF-7-PAX2
stable cell line, MCF-7 cells were firstly infected with virus
carrying pLV.ExSi.P/Hygro-CMV-TET3G and selected
with 200 μg/ml hygromycin B for 20 days to get MCF-7-
Tet3G cell line. Then, MCF-7-Tet3G cell line was infected
with virus containing pLV.ExSi.P/Puro-TRE3G-PAX2/HA
and selected with 200 μg/ml hygromycin B and 2 μg/ml
puromycin for 20 additional days.
Western blotting
Cells were lysed (50 mM Tris-HCl, pH 7.4; 100 mM NaCl;
1 mM EDTA; 1 mM EGTA; 1 mM NaF; 0.1% SDS; 0.5%
sodium deoxycholate; 1% Triton-X-100; 2 mM sodium
orthovanadate; Protease Inhibitor Cocktail (Thermo
Fisher)). Protein lysate was resolved using precast SDS-
PAGE gels, and transferred to PVDF membrane. Blots
were blocked and incubated overnight at 4 °C with primary
antibodies, followed by three washes with TBS with 0.1%
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Tween 20 (TBST). Then, membranes were incubated with
HRP-conjugated second antibodies against corresponding
species of primary antibodies for 1 h and followed by three
washes with TBST. Finally, membranes were developed
with SuperSignal™ West Pico (Thermo Fisher) or Super-
Signal™ West Femto (Thermo Fisher). Primary antibodies
used are as bellow: PAX2-HA tag (ab9110) antibodies
were purchased from Abcam; IRF1 (8478S), caspase 7
(9492S), caspase 8 (4790s), RPL13a (2765S), and β-Actin
(4970S) antibodies were from Cell Signalling Technology.
Cell proliferation assay
Cell proliferation assay was performed with the Incucyte
system (Essen BioScience). MCF-7-PAX2 cells were plated
in a 24-well plate at 10% confluence (0.02 × 106/well) in
full culture media. On the first day after plating, cells were
treated with 1 μM Tam (H7905, Sigma) and doxycycline
(Dox). ZR-75-1 were transfected with pCI-neo empty vec-
tor or pCI-neo-PAX2-HA vector, which is followed by
trypsinization and subplating into a 96-well plate 4–6 h after
transfection. Cells were treated with Veh or 1 μM Tam in
the following day. The proliferation (termed phase contrast
in the Incucyte software) was monitored by the Incucyte
system every 3 h for at least 96 h. For MCF-7-PAX2 and for
ZR-75-1 were used three and four wells (technical repli-
cates) for each treatment, respectively. The data were
plotted showing the average of phase contrast with standard
deviation as the error bar.
RNA extraction and real-time PCR
MCF-7-PAX2 cells were plated into a six-well plate in full
culture media with 5% of FBS with or without siRNA
transfection (siNon-targeting or siIRF1). MCF-7 and ZR-75-1
cells were transfected with pCI-neo, pCI-neo-IRF1, or pCI-
neo-PAX2-HA. Cells were used for RNA extraction and total
RNA was isolated with TRIzol Reagent (15596018, Invitro-
gen) following the manufacturer’s protocol.
A total of 2 μg of RNA was used for cDNA synthesis
with SuperScript III (18080093, Invitrogen), and real-time
PCR was performed with Power SYBR Green PCR Master
Mix (4368702, Applied Biosystems). Primers for genes
tested are listed in Supplementary Materials.
Reference genes for normalization were selected fol-
lowing geNorm algorithm [18]. Eight reference genes
(UBC, GADPH, RPL13A, SDHA, ACTB, B2M, HMBS,
HPRT1) were tested in all cell lines and treatments, among
them RPL13A and UBC were selected for MCF-7, and
RPL13A and SDHA for ZR-75-1. In all real-time PCR
experiments, three technical replicates were included for
each sample, and two-tailed Student’s t test was done to
determine the p value between samples.
GRO-seq library preparation
Global run-on and library preparation for sequencing was
performed as previously described [19] with minor mod-
ifications. Briefly, 2 × 106 MCF-7-PAX2 cells were plated
into each 15 cm plate in DMEM with 5% FBS. Three days
after plating, cells were treated with Veh (control) or 50 ng/
ml Dox to overexpress PAX2. Sixteen hours after Dox
treatment, cells were treated with either Veh (control) or
1 μM 4-Hydroxytamoxifen (Sigma). Nuclei isolation was
performed 6 h after stimulation and 5 × 106 nuclei were used
for each run-on reaction. Two biological replicates were
produced for each treatment (control, Dox, Tam and Dox+
Tam). Br-UTP was incorporated into on-going transcription
by run-on reaction that was performed at 30° for 5 min.
Total RNA was extracted with TRIzol Reagent (Life
Technologies) and fragmented with RNA Fragmentation
Reagent (Life Technologies). Fragmented RNA was pur-
ified with P-30 column (Bio-Rad, Hercules, CA, USA),
which was followed by T4 polynucleotide kinase (New
England Biolabs) treatment to dephosphorylate the 3′ end of
RNA fragments. Br-UTP labeled RNA was enriched twice
with anti-BrdU beads (Santa Cruz Biotechnology) and
precipitated overnight. Poly(A) tailing was done using E.
coli Poly(A) Polymerase (New England Biolabs), followed
by reverse transcription with oNTI-223-index:
/5Phos/GATCGTCGGACTGTAGAACTCTGAAC/iSp18/
TCAGACGTGTGCTCTTCCGATCTTTTTTTTTTTTTTT
TTTTTVN, which allows custom barcoding. Exonuclease I
(New England Biolabs) was used to remove excess oligo
after reverse transcription. DNA–RNA duplex was purified
with ChIP DNA Clean & Concentrator Kit (Zymo Research
Corporation) followed by RNAse H treatment. cDNA was
circularized with CircLigase II (Epicentre) and amplified
with oNTI-201: AATGATACGGCGACCACCGACA
GGTTCAGAGTTCTACAGTCCGACG and oNTI-200:
CAAGCAGAAGACGGCATACGAGATXXXXXXGTG
ACTGGAGTTCAGACGTGTGCTCTTCCGATCT (XXX
XXX is barcode used for specific sample) for 12–14 cycles.
Final PCR product was purified by running 10% TBE gel
and cleaned up. Libraries were sequenced on Illumina
Genome Analyzer HiSeq 2000 according to the manu-
facturer’s instructions.
GRO-seq data processing and data analysis
GRO-seq data were first trimmed from the 3′ end to remove
PolyA tail with Homer tools followed by quality filtering with
FASTX Toolkit with the criteria that minimum 97% of base
pairs should have quality scores higher than 10. Trimmed and
quality-filtered data were aligned to human genome hg19 with
Bowtie [20]. Differential expression analysis was performed
with edgeR [21], genes with RPKM> 0.5 were considered
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expressed, 1.5-fold change with FDR < 0.05 was considered
significant differential expression. Intergenic transcripts
(eRNAs) were called by Homer software with a minimum
length of 300 bp. Differentially expressed eRNAs were
detected by following the same criteria to coding genes.
Regulated eRNAs were annotated with Homer software
according to the nearest gene. Regulated genes, which were
the nearest genes of regulated eRNAs in the same treatment,
were selected for further analysis.
Chromatin immunoprecipitation
PAX2 genomic distribution was identified by using the
cross-linking ChIP protocol as described previously [22]. A
total of 2 × 106 MCF-7-PAX2 cells were plated into each
15 cm plate in DMEM with 5% FBS 3 days after plating,
cells were treated with Veh (control) or 50 ng/ml Dox to
overexpress PAX2. Sixteen hours after Dox treatment, cells
were treated with either Veh (control) or 1 μM 4-
Hydroxytamoxifen for 6 h. Then, cells were fixed for
10 min with 1% formaldehyde and then quenched with
glycine (125 mM). Chromatin was incubated overnight at
4 °C with Chip grade HA tag antibody (10 μg of ab9110)
and equal amounts of Protein A&G Agarose Beads (Life
Technologies). Immunoprecipitated genomic DNA was sent
to Norwegian sequencing center for library preparation and
sequenced with Illumina NextSeq 500.
ChIP-seq data analysis
ChIP-seq raw data were aligned to human genome assembly
hg19 with Bowtie. Then, PCR duplicates were removed
with SAMtools [23], followed by peak calling with MACS2
[24] with q value cutoff 0.01. Correlation between replicates
was analyzed with deepTools [25]. Overlap between data-
sets was analyzed with bedtools [26]. ER ChIP-seq data
were adapted from previous study [27], and was processed
as mentioned above.
Pathway enrichment analysis
Pathway enrichment analysis was performed with Metas-
cape (http://metascape.org) [28] and GSEAPreranked in
Gene set enrichment analysis [29] with regulated gene lists
derived from GRO-seq analysis.
Analysis of mRNA expression in breast cancer
sections
Total RNA (150 ng) was shipped to the NanoString nCounter®
Human mRNA Expression Assay analysis. RNA was incu-
bated in the presence of mRNA specific probes. To account
for minor differences in hybridization and purification
efficiencies raw data were adjusted using a technical normal-
ization factor calculated from six internal positive spike con-
trols present in each reaction. Background hybridization was
corrected by deducting the negative control mean plus two
standard deviations calculated from eight negative controls.
Annexin V assay
The Annexin V assay measuring the externalization of
phosphatidylserine (PS) was carried out by using Incucyte
Annexin V Red Reagent (4641, Essen BioScience). MCF-7-
PAX2 cells were plated into a 96-well plate in full media with
5% FBS with or without transfection of siRNA (siNT or
siIRF1). Twenty-four hours after plating cells were treated
with Veh, 1 µM Tam, 50 ng/ml Dox, or the combination of
both. At the same time the Incucyte Annexin V Red Reagent
was added into the media in a 1:200 dilution. ZR-75-1 cells
were first transfected with pCI-neo or pCI-neo-PAX2-HA,
followed subplating into 96-well plate 4–6 h after transfection.
Cells were treated with Veh or 1 µM Tam from the following
day. The signal of Annexin V was measured every 2 h by
quantifying total red object integrated intensity signal (total
RCU), and the cell confluence was measured by phase con-
trast. Relative Annexin V signal was calculated by normal-
izing the RCU parameter against cell confluence.
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